Phase 1/2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Background:
Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.
Objective:
To test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC.
Eligibility:
People aged 18 years and older with HTC. The HTC must have failed to respond to conventional radioactive treatment; it must also have spread to other parts of the body.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans and a test of their heart function.
177LuDOTA-EB-TATE is infused into a vein. Participants will receive 4 infusions spaced 8 to 12 weeks apart. They will stay in the hospital for 4 to 10 days after each infusion. During and after each infusion, participants will remain in a lead-lined room until their radiation levels go down; this usually takes about 24 hours.
Participants will have 4 to 6 follow-up visits in the weeks after each infusion. Procedures will vary at each visit, but may include more imaging scans; blood and urine tests; and tests of heart function. Participants will have 2 single-photon emission computerized tomography (SPECT) scans. SPECT scans show where the study drug is sticking to tumors or maybe other parts of their body. They will lie on a table while a machine rotates around them. Participants will fill in questionnaires about how their thyroid condition affects their life.
Participants will have follow-ups visits for 5 years after their last study treatment.

Start Date07 Jul 2026

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05475210

/ Unknown statusPhase 1

Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.

Start Date18 Jun 2022

Sponsor / Collaborator

Molecular Targeting Technologies, Inc.

[+1]

NCT03308682

/ Unknown statusPhase 1IIT

Safety and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors

This is an open-label, non-controlled, non-randomized study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluation safety and dosimetry of 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors. A single dose of 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE will be injected intravenously. and monitored at 2, 24, 72,120 and 168 hours post-injection with semiquantitative method based on quantitative single-photon emission computed tomography/computed tomography (SPECT/CT) performance.

Start Date30 Apr 2017

Sponsor / Collaborator

Peking Union Medical College Hospital

[+1]

100 Clinical Results associated with 177Lu-DOTA-EB-TATE

100 Translational Medicine associated with 177Lu-DOTA-EB-TATE

100 Patents (Medical) associated with 177Lu-DOTA-EB-TATE

Literatures (Medical) associated with 177Lu-DOTA-EB-TATE

01 Jun 2023·Clinical nuclear medicine

Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE With and Without Amino Acid Infusion

Article

Author: Guochang Wang ; Zhaohui Zhu ; Qingxing Liu ; Jingjing Zhang ; Xiaoyuan Chen ; Yuanyuan Jiang

Purpose:

Kidney is considered to be one of the dose-limiting organs in peptide receptor radionuclide therapy (PRRT). Amino acid cocktail infusion has been applied to reduce renal absorbed dose by inhibiting the proximal tubular reabsorption of the radiopeptide. An Evans blue-modified 177Lu-labeled octreotate (177Lu-DOTA-EB-TATE) has an extended circulation in the blood, which may make the amino acid infusion unnecessary. The aim of this study was to evaluate the safety, biodistribution, and dosimetry of 177Lu-DOTA-EB-TATE with and without amino acid infusion.

Patients and Methods:

Ten patients with metastatic neuroendocrine tumors were randomly divided into 2 groups. The effect of amino acid infusion on renal uptake was assessed in a crossover randomized setting. Group A received 177Lu-DOTA-EB-TATE at a dose of 3.7 GBq without amino acid infusion for the first cycle and with amino acid infusion for the second cycle; group B received 177Lu-DOTA-EB-TATE at a dose of 3.7 GBq with amino acid infusion for the first cycle and without amino acid infusion for the second cycle. All patients underwent serial whole-body planar imaging at 1, 24, 96, and 168 hours and SPECT scan at 24 hours after radioligand administration. Abdominal CT was performed 2 days before PRRT for SPECT/CT fusion. The dosimetry was calculated using the HERMES software. Dosimetry evaluation was compared on a between-group and intrapatient basis.

Results:

Administrations of 177Lu-DOTA-EB-TATE with or without amino acids were well tolerated. No grade 4 hematotoxicity was observed in any of the patients. Grade 3 thrombocytopenia was reported in 1 patient. No nephrotoxicity of any grade was recorded. No significant difference was observed in creatinine (75.1 ± 21.7 vs 67.5 ± 18.1 μmol/L, P = 0.128), blood urea nitrogen (4.5 ± 0.8 vs 5.1 ± 1.4 mmol/L, P = 0.612), or GFR (109.3 ± 25.2 vs 100.9 ± 24.9 mL/min, P = 0.398) before and after PRRT. For each cycle, there was no significant difference in whole-body effective dose, kidney effective dose, as well as residence time of the kidneys between group A and B (P > 0.05). By intrapatient comparison, without and with amino acid infusion also did not show significant difference in whole-body effective dose (0.14 ± 0.05 vs 0.12 ± 0.04 mSv/MBq, P = 0.612), kidney effective dose (1.09 ± 0.42 vs 0.73 ± 0.31 mSv/MBq, P = 0.093), and residence time of the kidneys (2.95 ± 1.58 vs 3.13 ± 1.11 hours, P = 0.674).

Conclusions:

177Lu-DOTA-EB-TATE PRRT with and without amino acid infusion demonstrated a favorable safety profile in neuroendocrine tumor patients. Administration of 177Lu-DOTA-EB-TATE without amino acid infusion has acceptable slightly increased kidney absorbed dose and residence time of the kidneys, and does not affect kidney function. Further investigation in a larger cohort and long-term follow-up are warranted.

01 Jan 2022·Theranostics

Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors

Article

Author: Zhu, Zhaohui ; Wang, Guochang ; Zhang, Jingjing ; Liu, Qingxing ; Jiang, Yuanyuan ; Sui, Huimin ; Chen, Xiaoyuan ; Wang, Jiarou ; Wang, Rongxi

Rationale: This study aimed to assess the safety, efficacy, and survival of ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors (NETs). Methods: Thirty patients with metastatic NETs were prospectively enrolled and treated with ¹⁷⁷Lu-DOTA-EB-TATE (3 intended cycles at 8 to 12-week intervals, 3.7 GBq/cycle). Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The treatment response was graded according to RECIST 1.1 and PERCIST 1.0 criteria. Kaplan-Meier analysis was performed to calculate progression-free survival (PFS) and overall survival (OS). Results: Patients tolerated therapy well without acute adverse effects. During peptide receptor radionuclide therapy (PRRT), no grade 4 toxicity was observed in any of the patients; grade 3 hematotoxicity was recorded in 4 patients, including grade 3 thrombocytopenia in 4 patients (13.3%) and grade-3 anemia in 1 patient (3.3%); grade 3 hepatotoxicity was recorded in 1 (3.3%) patient, and no grade 2/3/4 nephrotoxicity was observed. On long-term follow-up, none of the patients developed grade 4 hematotoxicity or nephrotoxicity of any grade, reversible grade 3 hematotoxicity (thrombocytopenia) occurred in 1 patient. There was no incidence of leukemia or myelodysplastic syndrome for the duration of follow-up. Of 27 patients with RECIST-measurable disease, partial response and stable disease were seen in 9 and 14 patients, respectively, resulting in a response rate of 33.3% and disease control rate of 85.2%. Of 29 patients evaluable for response on ⁶⁸Ga-DOTATATE PET/CT, 14 had partial response and 11 had stable disease, with a response rate of 48.3% and disease control rate of 86.2%. The follow-up period ranged from 5 to 57 months after the first ¹⁷⁷Lu-DOTA-EB-TATE PRRT with a median follow-up of 46 months. The median PFS was 36 months, and the median OS was not reached. Ki-67 index of greater than 10% was associated with poorer PFS (P = 0.012). Conclusions: Our results suggest that PRRT with approximately 3.7 GBq ¹⁷⁷Lu-DOTA-EB-TATE has acceptable toxicity profile and is effective in treating metastatic NET with high disease control rate. In addition, ¹⁷⁷Lu-DOTA-EB-TATE achieved a favorable survival outcome with encouraging PFS.

01 Mar 2021·Journal of nuclear medicine : official publication, Society of Nuclear MedicineQ1 · MEDICINE

Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of¹⁷⁷Lu-DOTA-EB-TATE

Q1 · MEDICINE

Article

Author: Chen, Xiaoyuan ; Wang, Rongxi ; Guo, Hua ; Zhu, Zhaohui ; Wang, Hao ; Jacobson, Orit ; Liu, Qingxing ; Sui, Huimin ; Zhang, Jingjing ; Zang, Jie ; Cheng, Yuejuan ; Ren, Jiakun

This study aimed to evaluate the safety and efficacy of multiple cycles of ¹⁷⁷Lu-DOTA-Evans blue (EB)-TATE peptide receptor radionuclide therapy (PRRT) at escalating doses in neuroendocrine tumors (NETs). Methods: Thirty-two NET patients were randomly divided into 3 groups and treated with escalating doses. Group A received 1.17 ± 0.09 GBq/cycle; group B, 1.89 ± 0.53 GBq/cycle; and group C, 3.97 ± 0.84 GBq/cycle. The treatment was planned for up to 3 cycles. Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Treatment response was evaluated according to the European Organisation for Research and Treatment of Cancer criteria and modified PERCIST. Results: Administration of PRRT was well tolerated, without life-threatening adverse events (CTCAE grade 4). CTCAE grade 3 hematotoxicity was recorded in 1 patient (16.6%) in group B (thrombocytopenia) and 3 patients (21.4%) in group C (thrombocytopenia in 3, anemia in 1). CTCAE grade 3 hepatotoxicity (elevated aspartate aminotransferase) was recorded in 1 patient in group A (8.3%) and 1 patient in group C (7.1%). No nephrotoxicity was observed. According to the criteria of the European Organisation for Research and Treatment of Cancer, the overall disease response rates were similar in groups A, B, and C (50.0%, 50.0%, and 42.9%, respectively), and the overall disease control rates were higher in groups B (83.3%) and C (71.5%) than in group A (66.7%). According to modified PERCIST, a lower disease response rate but a similar disease control rate were found. When a comparable baseline SUV_max ranging from 15 to 40 was selected, the percentage change in SUV_max increased slightly in group A (2.1% ± 40.8%) but decreased significantly in groups B and C (-38.7% ± 10.0% and -14.7% ± 20.0%, respectively) after the first PRRT (P = 0.001) and decreased in all 3 groups after the third PRRT (groups A, B, and C: -6.9% ± 42.3%, -49.2% ± 30.9%, -11.9% ± 37.9%, respectively; P = 0.044). Conclusion: Dose escalations of up to 3.97 GBq/cycle seem to be well tolerated for ¹⁷⁷Lu-DOTA-EB-TATE. ¹⁷⁷Lu-DOTA-EB-TATE doses of 1.89 and 3.97 GBq/cycle were effective in tumor control and more effective than 1.17 GBq/cycle.

News (Medical) associated with 177Lu-DOTA-EB-TATE

10 Jun 2026

·www.businesswire.com

MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, today announced updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches. Key Clinical Highlights from 81 Treated GEP-NET Patients Approximately 8-fold higher tumor uptake compared with conventional PRRT Potential two-cycle treatment regimen versus the conventional four-cycle PRRT Clinical activity achieved using only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT The findings further validate MTTI's proprietary Evans Blue (EB) technology platform, which utilizes reversible albumin binding to extend circulation time, enhance tumor uptake, and increase tumor retention. Preclinical studies have demonstrated up to 26-fold higher tumor retention compared with conventional radiopharmaceutical approaches, supporting broad applicability across multiple radionuclides, targeting vectors, and tumor types. "The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform," said Chris Pak, Chairman and Chief Executive Officer of MTTI. "By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential to enhance the therapeutic index of radiopharmaceuticals across multiple cancers and with both beta- and alpha-emitting radionuclides. The combination of enhanced tumor uptake, prolonged tumor retention, favorable clinical responses, and robust safety observations supports the continued development of EBTATE and highlights the broader potential of the Evans Blue platform to improve targeted radiotherapeutics across a wide range of solid tumors." "EBTATE achieved markedly higher tumor uptake and longer tumor retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile," said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center and recipient of the 2026 Castle Connolly America's Top Doctor Award. "The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT. This data from NET patients supports continued clinical development and further evaluation of a streamlined treatment regimen." About Molecular Targeting Technologies, Inc. Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics for cancer. Powered by its proprietary Evans Blue (EB) technology platform, MTTI is advancing a pipeline of beta- and alpha-emitting radiopharmaceuticals designed to improve tumor targeting, increase therapeutic index, and enhance treatment efficiency. In addition to EBTATE, MTTI is developing 225Ac-EBTATE for small cell lung cancer, where preclinical studies have demonstrated comparable efficacy to 225Ac-DOTATATE at approximately 40% of the administered dose. For more information, visit www.mtarget.com. Forward-Looking Statements This press release contains forward-looking statements regarding the potential safety, efficacy, clinical benefits, development plans, and commercial opportunities of EBTATE and MTTI's Evans Blue technology platform. Actual results may differ materially from those indicated by such forward-looking statements. EBTATE is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

Radiation TherapyAACRClinical ResultClinical Study

28 May 2026

·www.biospace.com

Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announced the clinical findings of the Next-Generation PRRT, ¹⁷⁷Lu-DOTA-EB-TATE to treat GEP-NET Patients. The Phase 1 dose-escalation and dosimetry study will be presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 29–June 3, 2026, in Los Angeles, California. Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies like Peptide Receptor Radionuclide Therapy (PRRT). While 177 Lu-DOTATATE has demonstrated efficacy, its rapid clearance limits tumor radiation delivery and may increase renal toxicity risk. “Our Clinical findings suggest that EBTATE may achieve meaningful clinical responses after only two treatment cycles while delivering approximately 12.5% of the cumulative radioactivity required for standard PRRT,” said Chris Pak, Chairman and Chief Executive Officer of MTTI. “If validated in larger studies, EBTATE could represent a transformative advance in radiopharmaceutical therapy, shortening treatment duration, reducing radiation exposure, and enabling physicians to evaluate efficacy much earlier than is possible today.” “EBTATE achieved substantially higher tumor uptake and prolonged retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile, with no kidney toxicity observed for one year follow-up,” said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center. “The ability to deliver greater tumor radiation with significantly less administered radioactivity positions EBTATE as a potentially transformative PRRT. These data also support the possibility of a streamlined two-cycle regimen, enabling earlier evaluation of treatment efficacy.” The presentation entitled, “Next-Generation PRRT” by Dr. Bodei (poster # 261874). The poster has also been selected for a 10-minute oral presentation during the 2026 Patient Education Day NETS Program Schedule ( ), on 5/31/26 during the SNMMI meeting. MTTI will present its proprietary Evans Blue (EB) albumin-binding technology platform at Booth #1758 during the SNMMI Annual Meeting, featuring clinical data from 81 GEP-NET patients and compelling preclinical results. MTTI’s EB technology enhances tumor targeting through reversible albumin binding, delivering up to 26-fold greater tumor retention in preclinical models and approximately eight-fold higher tumor uptake in patients compared with conventional DOTA-TATE. These findings position the platform as a potentially transformative approach for next-generation radiopharmaceuticals, with the potential to improve efficacy, expand therapeutic opportunities, and create significant strategic value. About Molecular Targeting Technologies, Inc. Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics for cancer. Powered by its proprietary Evans Blue (EB ) technology platform, MTTI is advancing Ac-225 and Lu-177–based PRRT agents designed to enhance tumor targeting and retention, potentially enabling improved efficacy, lower radiation exposure, and earlier therapeutic responses. For more information, please visit . Contacts Media Contact: Chris Pak; Email: cpak@mtarget.com

09 Dec 2024

·pipelinereview.com

MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors

WEST CHESTER, PA, USA I December 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary 225 Ac-EBTATE against SSTR2 NET cancers online in the European Journal of Nuclear Medicine. (“Long acting 225 Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive neuroendocrine tumors” ( https://rdcu.be/d2lCG ). Professor Humphrey Fonge of the Université de Laval and lead author commented, “At just 40% of the administered dose reported for 225 Ac-DOTATATE, 225 Ac-EBTATE produces enhanced anti-tumor efficacy in Small Cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as shown with complete tumor remissions. At a therapeutic dose of 2x 34 kBq, 225 Ac-EBTATE showed general safety for 28 days after blood biochemistry analysis, CBC, and histopathological examination of major organs and tissues. We demonstrated that 225 Ac-EBTATE was effective against human small-cell lung cancer (SCLC) with 80% complete remission and 100% survival in preclinical models.” MTTI has licensed commercial use rights for the patented Evans blue (EB) technology from the National Institute of Biomedical Imaging and Bioengineering (“ NIBIB ”), part of the National Institutes of Health (“ NIH ”). This platform is the basis for the best-in-class, new generation, collection of targeted radiopharmaceuticals (TRP). EB binds to serum albumin, extending in vivo circulatory half-life and tumor residence time, enhancing up to 30-fold uptake at a tumor and enabling good efficacy with significantly lower radiopharmaceutical activity and fewer dosing cycles vs. the current standard of care. Our 3-year follow up of 177 Lu-EBTATE in patients* (N=30) with metastatic neuroendocrine tumors, demonstrated good safety with no nephro- or hepatoxicity and 86% disease control rate using only 40% of the administered dose of 177 Lu-DOTATATE. Dr. Jean-Mathieu Beauregard, MD, Associate Professor of Department of Radiology of Université Laval, said, “I am encouraged to see the positive results of 225 Ac-EBTATE in treating small cell lung cancer and Pan-neuroendocrine tumor (NET) in preclinical studies. I look forward to working with MTTI and Professor Fonge to translate this into the clinic.” Dr. Chris Pak, President & CEO of MTTI commented “ 225 Ac-EBTATE effectiveness was encouraging, paralleling the clinical superiority of 177 Lu-EBTATE. We look forward to collaborating with Professors Beauregard and Fonge to drive 225 Ac-EBTATE into clinical trials in 2025.” Molecular Targeting Technologies, Inc. (MTTI) . Molecular Targeting Technologies, Inc. is a private, clinical stage biotech developing targeted radiopharmaceuticals (TRP) for rare cancers. MTTI is committed to building value by translating innovative TRP to improve human health. For more information: www.mtarget.com . *Jiang Y, Liu Q, Wang G, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437-6445. SOURCE: Molecular Targeting Technologies Inc

Clinical Result

100 Deals associated with 177Lu-DOTA-EB-TATE

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thyroid Cancer, Hurthle Cell	Phase 2	United States	National Institute of Diabetes & Digestive & Kidney Diseases	07 Jul 2026
Apudoma	Phase 1	United States	Molecular Targeting Technologies, Inc.	18 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2026	Phase 1	Neuroendocrine Tumors somatostatin receptor (SSTR) overexpression	6	177Lu-DOTA-EB-TATE 1.85 GBq	omnuuguvcs(rkzwglavgp) = Hematologic toxicity was dose-limiting, with one patient in this study experiencing persistent Grade 3 febrile neutropenia at the 3.70 GBq dose level. Another patient from an external cohort also experienced a dose-limiting toxicity (DLT) at the same dose level, knhwzvimdr (bfbflnrtpz )	Positive	27 May 2026
NCT03478358 (Pubmed \| Clin Nucl Med)	Phase 1	-	10	177Lu-DOTA-EB-TATE without amino acid infusion	socksmmjxp(wwukagrtfu) = irgglepzna xufcgdjnly (cooipuuccn ) View more	-	18 Apr 2023
				177Lu-DOTA-EB-TATE with amino acid infusion	socksmmjxp(wwukagrtfu) = lwlgdjijir xufcgdjnly (cooipuuccn ) View more
SNMMI2020	Not Applicable	Advanced Neuroendocrine Neoplasm	-	Group A (1.17 ± 0.09 GBq/dose)	sgifvtmknx(ieumsmwbol) = 0.63% (1/160) occurrence in all of the performed blood tests vnkuqcflvs (lqtdtuzcty ) View more	-	15 May 2020
				Group B (1.89 ± 1.53 GBq/dose)
NCT03478358 (Treatment Using 177Lu-DOTA-EB-TATE, Pubmed \| Eur J Nucl Med Mol Imaging)	Phase 1	Neuroendocrine Tumors	-	Group A	sghzulordr(fjjsrrlkwi) = oqiwcvnqou ydmuhafxhj (nstwlagbal )	-	01 Apr 2020
				Group C	sghzulordr(fjjsrrlkwi) = polojkijcx ydmuhafxhj (nstwlagbal )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

177Lu-DOTA-EB-TATE

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation